image descriptionimage description

At least half of people taking HUMIRA can expect a reduction in joint symptoms after just three months, and a reduction in skin symptoms after six months1,2

Are you are still experiencing symptoms from psoriatic arthritis despite being on treatment?

Are you on a treatment for psoriatic arthritis but not getting the relief you expect from the joint pain, and red, scaly skin patches known as plaques? You may be ready for a change to a treatment that may help you get back your ability to do your usual everyday tasks.

There are a variety of medical treatments available to treat psoriatic arthritis. Some are for joint symptoms and some are for skin symptoms:

  • non-steroidal Anti-Inflammatory Drugs (NSAIDs)
  • corticosteroids
  • disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate

these may not be enough to relieve symptoms in everyone.

Is it time to consider another psoriatic arthritis treatment? Ask about HUMIRA.

The government medicine funding agency, PHARMAC, fully subsidises HUMIRA if your psoriatic arthritis has not fully responded to other medicines prescribed by a specialist, and you meet other criteria required by PHARMAC. Your specialist will discuss whether HUMIRA is right for you, and whether you may qualify for PHARMAC funded treatment.

HUMIRA can help reduce both joint pain, and red, scaly skin patches known as plaques, which are common symptoms of psoriatic arthritis

HUMIRA is a biologic disease-modifying anti-rheumatic drug, also called a biologic DMARD, or simply ‘biologic’. HUMIRA works differently to conventional DMARDs because it works by identifying and blocking a specific source of inflammation that contributes to psoriatic arthritis symptoms, and it may be an option for you.

HUMIRA treatment is only available on prescription, so if you are not getting the relief you expect from your current psoriatic arthritis treatment, talk to your rheumatologist or dermatologist to see if HUMIRA is right for you.

Rheumatologists and dermatologists in New Zealand have been able to prescribe HUMIRA for psoriatic arthritis since 2006, so there is over ten years’ experience in New Zealand prescribing HUMIRA for psoriatic arthritis.

HUMIRA can be used alone, or with certain other medicines for psoriatic arthritis.

With HUMIRA at least 50% of people can expect a reduction in joint symptoms after being treated for just 3 months.1,2 It is also effective in reducing the skin symptoms in approximately 6 out of 10 people after 6 months1

In psoriatic arthritis irreversible damage to joints and bones can occur over time. In long-term studies in adults, x-rays showed that for patients treated with HUMIRA, joint damage did not worsen in the majority of people after 11 months of HUMIRA treatment and these effects were maintained for over two years.3,4 Therefore HUMIRA appears to be beneficial in preventing or minimising further joint damage in psoriatic arthritis.

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Mease P. J., et al. Arthritis Rheum. 2005;52:3279–89
  2. Gladman D, et al. J Rheumatol 2010;37:1898-1906
  3. Gladman D, et al. Arthritis Rheum. 2007;56:476-88
  4. Mease, P. J. et al. Ann Rheum Diss, 2009;68(5), 702–09.

NZ-HUM-0120 TAPS PP9594 Prepared May 2017

Learn how HUMIRA works

Watch this short video to get a better understanding of how HUMIRA targets and helps to block TNF.

How HUMIRA treatment works video transcript

Usually, your immune system defends your body from many of the things that can harm it. But when the system doesn’t work right, it can attack healthy tissues and organs. This is an autoimmune disease. One part of your immune system is a protein called TNF, which is produced naturally by the body’s immune system. But in certain autoimmune diseases, some people produce too much TNF. This often leads to inflammation. HUMIRA is a medication called a TNF blocker. It works by binding to TNF molecules and blocking them from attaching to and making cells behave in a way which leads to effects on health. In this way, HUMIRA helps reduce the damaging effects of excess TNF. Remember, although HUMIRA can’t stop your body’s overproduction of TNF it can reduce its effects.

The immune system can overproduce the TNF protein, which is one source of inflammation that contributes to the symptoms of psoriatic arthritis. HUMIRA targets and helps block TNF (a particular protein), reducing its inflammatory effects on the joints leading to the symptoms of joint pain, swelling, and stiffness, and on the skin of red, scaly and risen plaques.

Talk to your rheumatologist or dermatologist about whether HUMIRA is right for treating your psoriatic arthritis

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Mease P. J., et al. Arthritis Rheum. 2005;52:3279–89
  2. Gladman D, et al. J Rheumatol 2010;37:1898-1906
  3. Gladman D, et al. Arthritis Rheum. 2007;56:476-88
  4. Mease, P. J. et al. Ann Rheum Diss, 2009;68(5), 702–09.

NZ-HUM-0120 TAPS PP9594 Prepared May 2017

Find out what to expect when you start treatment with HUMIRA for moderate to severely active psoriatic arthritis

With HUMIRA some people may expect an improvement in joint symptoms in as little as two weeks, and for some people joint symptom improvements may take three months or longer.1

Start out on the right path by learning how to take HUMIRA correctly

The usual recommended dose for adults with psoriatic arthritis is a 40mg injection once every two weeks. Your rheumatologist or dermatologist will decide what dosage of HUMIRA you require and how often you need to administer the injection. Only inject as prescribed by them.

Humira is given by injection just under the skin. HUMIRA is available in either a pre-filled single use syringe, or pre-filled single use auto-injector pen and both come pre-loaded with the exact dose of medicine inside, so it comes ready to inject and you can do it by yourself. Your rheumatologist, dermatologist or nurse will be able to help you and be with you for your first injection however before long you will be able to do it by yourself, or if not, it can be given by another healthcare professional or a family member or friend after they have been trained to give injections. Also, for people on HUMIRA in New Zealand you can join the AbbVie Care support programme with access to a nurse to help you.

Watch these short videos to get a better understanding of how to inject HUMIRA.

Pen video also available in the following languages:
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0046

Syringe video also available in the following languages:    
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0047

Storage and travelling with HUMIRA

Keep HUMIRA in the outer carton until it is time to use it. HUMIRA must be kept in the refrigerator (+2° C to +8° C) but don’t allow it to freeze. If you are travelling the HUMIRA pre-filled pen or pre-filled syringe may be stored at room temperature (below +25° C) for a maximum period of 14 days, but it must be protected from light. Once removed from the refrigerator for room temperature storage, the syringe or pen must be used within 14 days or discarded even if it is returned to the refrigerator. If additional syringes or pens are being carried, they should be refrigerated (kept between 2°C–8°C).

Join AbbVie Care to receive an ice pack and order a travel wallet through www.abbviecare.co.nz or call 0800 848 243.

When planning to travel overseas it is important that you:

  • talk to your doctor about travelling with HUMIRA
  • carry a letter from your doctor detailing what HUMIRA is, how much you will be taking, and stating that it is for your own personal use
  • leave HUMIRA in its original packaging so it is clearly labeled with your name and dosage instructions (if you are taking HUMIRA pens/syringes with you)


AbbVie Care Support Programme helps take care of you

AbbVie Care is available to you when you are taking HUMIRA. Support from AbbVie Care is designed to complement the care you receive from your specialist and clinic nurse.
AbbVie Care provides personalised support to meet each person’s needs. The aim is by working together people can achieve better outcomes with their health and quality of life.

It’s easy to ENROL

JOIN AbbVie Care to get the best out of your HUMIRA treatment
• Go online to www.abbviecare.co.nz
• Call 0800 848 243

How AbbVie Care supports you:

AbbVie Care Nurse

AbbVie Care Nurse Support

– Home visits or phone calls to help with injecting^
– Scheduled phone calls to provide information and support
– An 0800 number to call when you have a question

AbbvieCare Sharps Disposal Programme

Sharps Disposal Programme

– Delivery of sharps container to safely dispose of your HUMIRA pens and syringes
– Access to pharmacy disposal of your sharps container

AbbvieCare Travel Wallet

Travel Wallet

– Designed to make travelling with HUMIRA safer and easier

Abbvie_Care_Welcome_Kit

Welcome Kit

– Information on all you need to know to get the best out of AbbVie Care
– Ice pack to assist with injecting


References:
All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.
^Home visits do not cover all of New Zealand. Your AbbVie Care Nurse will be able to discuss this with you when you join AbbVie Care.

  1. Mease P. J., et al. Arthritis Rheum. 2005;52:3279–89
  2. Gladman D, et al. J Rheumatol 2010;37:1898-1906
  3. Gladman D, et al. Arthritis Rheum. 2007;56:476-88
  4. Mease, P. J. et al. Ann Rheum Diss, 2009;68(5), 702–09.

NZ-HUM-0120 TAPS PP9594 Prepared May 2017

The following resources have been compiled to help you get support outside the HUMIRA AbbVie Care programme. We hope you find them useful.

mypsi

My Psoriasis

A New Zealand website provided by AbbVie which provides you with information about life with Psoriasis

www.mypsoriasis.co.nz

Psoriasis and Psoriatic Arthritis New Zealand Facebook

The Psoriasis and Psoriatic Arthritis NZ Facebook Group is a community for people with Psoriasis and Psoriatic Arthritis. The group welcomes new members to connect, share stories and tips and support one another.

Psoriasis and Psoriatic Arthritis New Zealand Facebook

Psoriasis Association (Southland)Psoriasis Association Southland

Main support network for people in New Zealand affected by psoriasis and psoriasis-related conditions.

www.psoriasis.org.nz

dermnet

DermNet New Zealand Trust

DermNet NZ provides authoritative information about skin diseases, conditions and treatment for patients and their health professionals.

http://www.dermnetnz.org

 logo_Arthritis-New-Zealand

Arthritis New Zealand

A national voluntary organisation which represents the interests of those with arthritis. Information on the condition and its treatment.
www.arthritis.org.nz

Arthritis Australia

www.arthritisaustralia.com.au

Arthritis Foundation USA

www.arthritis.org

New Zealand Rheumatology Association

www.rheumatology.org.nz

Australian Rheumatology Association

www.rheumatology.org.au

American College of Rheumatology

www.rheumatology.org

Double Whammy

An AbbVie organised and sponsored website (live June 2016) to help identify psoriatic arthritis and provide tools and guidance for your next steps.
www.doublewhammy.co.nz

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Mease P. J., et al. Arthritis Rheum. 2005;52:3279–89
  2. Gladman D, et al. J Rheumatol 2010;37:1898-1906
  3. Gladman D, et al. Arthritis Rheum. 2007;56:476-88
  4. Mease, P. J. et al. Ann Rheum Diss, 2009;68(5), 702–09.

NZ-HUM-0120 TAPS PP9594 Prepared May 2017